All In Biotech

NDA 208700 · Aaa USA INC

Lutathera

Lutetium Lu-177 Dotatate · Intravenous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jan 26, 2018

Approved uses

5

Original approval plus efficacy supplements

Registered trials

72

13 Phase 3, 27 recruiting

FAERS reports

5,819

2,380 serious, 712 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 15, 2026.

LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

Mechanism: Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 23, 2024 Supplement 31 · Efficacy · priority review OrphanLabel
  • Jun 13, 2022 Supplement 19 · Efficacy OrphanLetterLabel
  • May 29, 2020 Supplement 1 · Efficacy Label
  • May 28, 2020 Supplement 10 · Efficacy OrphanLetter
  • Jan 26, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • LUTATHERA · LUTETIUM LU-177 DOTATATE 10mCi/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Lutetium Lu-177 Dotatate" as an intervention, any sponsor and status, largest first.

All 72 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ill-defined disorder1,542
  • general physical health deterioration1,294
  • death441
  • malignant neoplasm progression364
  • nausea236
  • platelet count decreased231
  • covid-19198
  • fatigue193
  • diarrhoea189
  • disease progression174
  • laboratory test abnormal174
  • illness167

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20142
20172
201843
2019102
2020162
20211,352
2022829
20231,015
20241,043
2025832
2026436

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Aaa USA INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.